SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous

August 16, 2023

Abecma’s US Revenue Decreased; FDA Formally Puts DARIC33’s Trial on Hold; Manufacturing Capacity Ramping Up; 2seventy bio Q2 2023 Earnings Call Summary

Here is a brief preview of this blast: On Monday, August 14, 2seventy bio held its Q2 2023 earnings call (press release) acknowledging Abecma’s (BMS / 2seventy’s BCMA CAR-T) decline in US sales while disclosing updates on the SC-DARIC33's (drug-regulated CD33 CAR-T) Ph1 PLAT-08 clinical hold. Below, Celltelligence provides insights on the causes behind Abecma’s revenue decrease while discussing the potential delay that the clinical hold might cause on DARIC33’s clinical development.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.